AI assistant
Sending…
Processa Pharmaceuticals, Inc. — Director's Dealing 2025
Jan 31, 2025
35172_dirs_2025-01-31_1fb6662c-0743-4aaf-a901-b89a2ef28378.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2025-01-27
Reporting Person: Yorke Justin W (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-01-27 | Common Stock | P | 12400 | $0.7975 | Acquired | 12400 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 31232 | Indirect |
| Common Stock | 3737 | Direct |
More from Processa Pharmaceuticals, Inc.
Regulatory Filings
2026
Feb 19
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Regulatory Filings
2026
Jan 7
Regulatory Filings
2025
Dec 15
Major Shareholding Notification
2025
Nov 7
Interim / Quarterly Report
2025
Nov 6
Major Shareholding Notification
2025
Oct 15